Sulfasalazine/sorafenib: A novel antitumor combination therapy for HCC

Hepatocellular carcinoma (HCC) is a frequent and deadly human disease. The management of HCC has substantially changed in the past few decades. In recent decades, tremendous progress has been made toward better understanding the molecular mechanisms of oncogenic processes. Hepatocarcinogenesis is a very complex system of pathways and results from genetic alterations affecting many cellular signaling cascades. This book,therefore, provides a new metric of success for HCC treatment. Till now there is no gold standard treatment for HCC. Sulfasalazine/sorafenib combination therapy: A new hope for HCC patients. Now you can beat your cancer. von Shamaa, Marium und Wasfy, Mage